HomeCompareAMGN vs NUE

AMGN vs NUE: Dividend Comparison 2026

AMGN yields 2.77% · NUE yields 1.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMGN wins by $127.2K in total portfolio value
10 years
AMGN
AMGN
● Live price
2.77%
Share price
$349.00
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.2K
Annual income
$69,743.86
Full AMGN calculator →
NUE
NUE
● Live price
1.34%
Share price
$164.75
Annual div
$2.21
5Y div CAGR
36.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.0K
Annual income
$5,036.01
Full NUE calculator →

Portfolio growth — AMGN vs NUE

📍 AMGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGNNUE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGN + NUE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGN pays
NUE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGN
Annual income on $10K today (after 15% tax)
$235.27/yr
After 10yr DRIP, annual income (after tax)
$59,282.28/yr
NUE
Annual income on $10K today (after 15% tax)
$114.02/yr
After 10yr DRIP, annual income (after tax)
$4,280.61/yr
At 15% tax rate, AMGN beats the other by $55,001.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGN + NUE for your $10,000?

AMGN: 50%NUE: 50%
100% NUE50/50100% AMGN
Portfolio after 10yr
$100.6K
Annual income
$37,389.94/yr
Blended yield
37.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMGN right now

AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-0.4% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
NUE
Analyst Ratings
18
Buy
11
Hold
3
Sell
Consensus: Buy
Price Target
$179.67
+9.1% upside vs current
Range: $176.00 — $183.00
Altman Z
4.4
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGN buys
0
NUE buys
0
No recent congressional trades found for AMGN or NUE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGNNUE
Forward yield2.77%1.34%
Annual dividend / share$9.66$2.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.6%36.9%
Portfolio after 10y$164.2K$37.0K
Annual income after 10y$69,743.86$5,036.01
Total dividends collected$133.8K$15.0K
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusBuyBuy
Analyst price target$347.73$179.67

Year-by-year: AMGN vs NUE ($10,000, DRIP)

YearAMGN PortfolioAMGN Income/yrNUE PortfolioNUE Income/yrGap
1← crossover$11,111$411.31$10,884$183.64+$227.00AMGN
2$12,524$634.70$11,901$255.72+$623.00AMGN
3$14,394$993.52$13,092$357.77+$1.3KAMGN
4$16,987$1,585.83$14,512$503.54+$2.5KAMGN
5$20,776$2,599.19$16,242$714.13+$4.5KAMGN
6$26,645$4,414.70$18,402$1,022.61+$8.2KAMGN
7$36,373$7,863.06$21,172$1,482.33+$15.2KAMGN
8$53,826$14,907.12$24,836$2,182.08+$29.0KAMGN
9$88,231$30,636.84$29,850$3,275.00+$58.4KAMGN
10$164,151$69,743.86$36,975$5,036.01+$127.2KAMGN

AMGN vs NUE: Complete Analysis 2026

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →

NUEMaterials

Nucor Corporation manufactures and sells steel and steel products. The company's Steel Mills segment produces hot-rolled, cold-rolled, and galvanized sheet steel products; plate steel products; wide-flange beams, beam blanks, and H-piling and sheet piling products; and bar steel products, such as blooms, billets, concrete reinforcing and merchant bars, and special bar quality products. It also engages in the steel trading and rebar distribution businesses. This segment sells its products to steel service centers, fabricators, and manufacturers in the United States, Canada, and Mexico. Its Steel Products segment offers hollow structural section steel tubing products, electrical conduits, steel racking, steel joists and joist girders, steel decks, fabricated concrete reinforcing steel products, cold finished steel products, steel fasteners, metal building systems, insulated metal panels, steel grating and expanded metal products, and wire and wire mesh products primarily for use in nonresidential construction applications. This segment also engages in the piling distribution business. The company's Raw Materials segment produces direct reduced iron (DRI); brokers ferrous and nonferrous metals, pig iron, hot briquetted iron, and DRI; supplies ferro-alloys; and processes ferrous and nonferrous scrap metal, as well as engages in the natural gas drilling operations. This segment sells its ferrous scrap to electric arc furnace steel mills and foundries for manufacturing process; and nonferrous scrap metal to aluminum can producers, secondary aluminum smelters, steel mills and other processors, and consumers of various nonferrous metals. It serves agriculture, automotive, construction, energy and transmission, oil and gas, heavy equipment, infrastructure, and transportation industries through its in-house sales force; and internal distribution and trading companies. Nucor Corporation was incorporated in 1958 and is based in Charlotte, North Carolina.

Full NUE Calculator →
📬

Get this AMGN vs NUE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGN vs SCHDAMGN vs JEPIAMGN vs OAMGN vs KOAMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.